NSF/NFD is a very rare but very serious, and sometimes fatal, condition. It has been closely associated with the use of gadolinium-based contrast agents used in MRI’s and MRA’s, and so far has only occurred in people with renal insufficiency. Because there is no cure for NSF/NFD, and the condition is very resistant to treatment, there is currently a very heavy emphasis on prevention.
Patients with moderate to severe renal insufficiency are at the highest risk for developing NSF/NFD. Anyone with renal insufficiency should avoid gadolinium exposure if possible, but for some people, tests using the contrast agent are necessary. In any event, patients with any level of renal insufficiency should be informed of the risks involved, and have the opportunity to decide for themselves, while taking into consideration the advice of their doctors, whether the benefits outweigh the risks.
Dose
The experts in NSF strongly recommend that when tests using contrast agents are absolutely necessary for people with renal insufficiency, the lowest effective dose should be used, especially in those with advanced kidney disease.
Dialysis
Gadolinium is primarily removed from the body by the kidneys. Therefore, people whose kidneys are not functioning properly do not eliminate the gadolinium as quickly and effectively as patients with normal functioning kidneys. Patients with normal functioning kidneys eliminate one-half of the injected gadolinium in 90 minutes while those with moderate to severe renal insufficiency, the half life of gadolinium is extended to up to 30 hours or more. This allows the gadolinium to undergo a chemical change and become distributed throughout the organs of the body The gadolinium is allowed to remain in their systems long enough to get into the skin and cause NSF/NFD.
Hemodialysis immediately after testing may eliminate some of the gadolinium. Typically, two or three, or more, sessions are needed to remove the toxin, but by doing so quickly after testing, gadolinium may not have the chance to spread throughout the body.
Hemodialysis may not be safe for everyone. Many doctors believe that patients who are not already in dialysis should not use the procedure just for gadolinium removal, because initiating dialysis can mean a permanent dependence on the procedure. Each person must be individually evaluated, and the benefits and risks of dialysis must be carefully weighed.
Different gadolinium contrast agents
All gadolinium-based contrast agents are considered to carry a possible risk of causing NSF/NFD, but some are more dangerous than others. So far, of the five gadolinium-based contrast agents approved by the FDA, only three have been linked to NSF/NFD. Most cases have occurred after the use of Omniscan, and some after using Magnevist and OptiMARK.
Some experts worry that low-risk patients will be overly cautious and go without the tests that they need. Each case has to be considered individually based on risk factors and the level of need for tests using the contrast agent.
If you believe you have developed NSF, we strongly advise you to contact your physician for an examination which may involve a skin biopsy. If you are, in fact, diagnosed with NSF, you should consult with an attorney experienced in handling NSF and other pharmaceutical injury cases
Posts Tagged ‘Kidney Disease’
Anemia in its various forms is the most common blood condition in the United States, affecting anywhere between 2 and 10-percent of Americans. Anemia is considered a symptom of disease, rather than a disease in itself.
The body’s ability to sustain the correct number of red blood cells requires cooperation of the bone marrow, kidneys, and nutrients circulating within the blood. If one of these systems is not working properly, the body may develop a form of anemia.
Normocytic anemia is a condition in which the body does not maintain an adequate amount of healthy red blood cells. This reduces the blood’s ability to transfer a sufficient amount of oxygen to the tissues.
There are two forms of Normocytic Anemia. Congenital normocytic anemia, caused by the breaking up of red blood cells, is a condition a person is born with. Acquired normocytic anemia, the more common form, is most often the result of chronic illness or disease. Rheumatoid arthritis, cancer, kidney disease, and autoimmune diseases are some of the diseases that may lead to normocytic anemia.
Normally normocytic anemia will progress slowly. Initially the person may have no symptoms. Eventually the person may become pale, overly tired. As the condition progresses, the person may experience any array of symptoms, including shortness of breath, low blood pressure, a fast or irregular heartbeat, chest pain, dizziness, and/or general weakness.
Normocyctic anemia is diagnosed through a complete medical history, a physical exam, and a routine blood test called a CBC (Complete Blood Count). Among other things, this blood test measures the levels of red blood cells and hemoglobin in the blood. A portion of the blood will likely be examined under a microscope. This will reveal the number of blood cells, as well as the size, shape, and color. Normocytic anemia is the diagnosis given when the patient is found to have a low number of normal-sized red blood cells.
Once diagnosed, the doctor may wish to order further testing to determine the cause of the anemia. Treatment of normocytic anemia preferably targets the root cause. Occasionally, in severe cases, the doctor may recommend a transfusion of red blood cells or shots of erythropoietin. Erythropoietin is a hormone normally produced by the kidneys. Manufactured under various brand names, this medication induces the bone marrow to produce more red blood cells.
A person diagnosed with anemia will need to have follow-up visits with his or her doctor in order to determine the response to treatment. Repeat blood tests will be ordered to monitor the number of red blood cells.


